Sparsentan for Focal Segmental Glomerulosclerosis

(MedPage Today) -- Focal segmental glomerulosclerosis (FSGS) still lacks an FDA-approved therapy, but late-breaking post hoc results from the phase III DUPLEX trial -- presented at the National Kidney Foundation Spring Clinical Meeting -- and...